

PRESS RELEASE

Ad hoc announcement pursuant to Art. 53 LR

Date 19 January 2023
Contact Investor Relations: Felix Burkhard, CFO Galenica Group
Media Relations: Christina Hertig, Head of Corporate Communications
Topic 2023 Annual General Meeting: Change to the Board of Directors of the Galenica Group

2023 Annual General Meeting: Change to the Board of Directors of the Galenica Group

At the Annual General Meeting on 3 May 2023, the Board of Directors of the Galenica Group will put forward Markus R. Neuhaus to shareholders for election as Chairman of the Board of Directors.

The current Chairwoman of the Board of Directors Daniela Bosshardt has been a member of Galenica's Board of Directors for 15 years and Chairwoman of the Board since 2019. After this long period of time, she has decided to step down from her position at Galenica and will not stand for re-election at the Annual General Meeting.

After a total of 13 years on the Board of Directors of Galenica, Michel Burnier will also not stand for re-election at the next Annual General Meeting.

To replace the two departures, the Board of Directors will put forward Solange Peters and Jörg Zulauf to the shareholders as new members of the Board of Directors.

Daniela Bosshardt has played a key role in shaping and driving the further development of Galenica

Daniela Bosshardt has been guiding the fortunes of Galenica for 15 years. She was first elected to the Board of Directors of the former Galenica Group in 2008. As part of the IPO of Galenica Santé, she also became a member of the Board of Directors of the then newly listed company in 2017 and in 2019 she took over as Chairwoman of the Board of Directors.

During this time, Daniela Bosshardt played a key role in shaping and driving the further development of Galenica. For example, she led the recruitment process for a new CEO, which led to the appointment of Marc Werner, who took up his new role in 2020. Since then, Daniela Bosshardt has driven forward and supported the further development of the strategic direction. To that end, she also strengthened the expertise and other necessary competencies in the Board of Directors with the appointments of Markus R. Neuhaus, Pascale Bruderer and Judith Meier. At the same time, she and the Board of Directors made promoting and supporting the transformation of the Galenica Group and the increased inclusion of sustainability goals as an integral part of overall corporate management a high priority.

After having served Galenica as a member of the Board of Directors for 15 years, Daniela Bosshardt has decided that the time has come to focus on other areas in the future: "Galenica is excellently positioned as a company and is managed by a diversified Board of Directors with experienced, competent and complementary individuals. The Group's strategic direction has been defined and is being implemented by true professionals. After 15 years on the Board of Directors of Galenica, it is therefore a good time for me to put the fortunes of Galenica in new hands."

The Board of Directors deeply regrets Daniela Bosshardt's decision but understands her reasoning. It will pay tribute to Daniela Bosshardt's achievements at a later date.

Markus R. Neuhaus, an extremely experienced business personality, will take over as Chairman of the Galenica Group

The Board of Directors will put forward Markus R. Neuhaus as the new Chairman of the Board of Directors at the Annual General Meeting. He has been a member of the Board of Directors of Galenica since 2019, has a PhD in law, and has accompanied and supported the Group since the beginning of its transformation and strategic development.

To date, he has contributed his in-depth expertise in financial and economic matters as Chairman of the Audit & Risk Committee and as a member of the Remuneration Committee. His many years of management experience as CEO, member of the Board of Directors and Chairman of various companies, his experience in sustainability topics as well as his extensive knowledge of trade associations, were particularly relevant to the Governance, Nomination & Sustainability Committee.

With Markus R. Neuhaus, an extremely experienced business personality will take over as Chairman of the Galenica Group. After many years as CEO and Chairman of the Board of Directors of PwC Switzerland and various European and global roles in the PwC network, he holds various board mandates.

In addition to his many years of consulting experience in corporate strategy and management, he also has specific expertise and know-how in regulatory matters, which is a key and strategically highly relevant topic for Galenica. Markus R. Neuhaus will also bring onboard his broad network in Swiss business and politics to his future role as Chairman of the Board of Directors.

Michel Burnier, a long-serving member, is leaving the Galenica Board of Directors

Michel Burnier, honorary professor in the department of nephrology and hypertension at Lausanne University Hospital (CHUV), is a long-serving member of the Galenica Group's Board of Directors. He joined the Board of Directors of what was then Galenica in 2010 and has been a member of the Board of Directors of the current Galenica since the IPO in 2017. He will not be standing for re-election at the 2023 Annual General Meeting. The Board of Directors would like to thank Michel Burnier for his valuable contribution and many years of service. The Board of Directors will pay tribute to his achievements at a later date.

Two new members to be put forward for election to the Board of Directors

The Board of Directors will put forward two new members to shareholders for election to the Board of Directors at the upcoming Annual General Meeting:

Solange Peters (1972) studied medicine at the University of Lausanne, graduating with an MD-PhD. In 2002, she joined the Centre Hospitalier Universitaire de Lausanne (CHUV), where she worked in internal medicine and, since 2006, in oncology. She is currently a professor at the University of Lausanne and head of the department of medical oncology at CHUV. With more than 500 publications in the most important medical journals, she is one of the world's leading experts in lung cancer.

In addition, Solange Peters is involved in various health organisations. For example, she has been a member of ESMO (European Society for Medical Oncology) for over 10 years and has chaired it for the past two years. She has also been President of the ICF (International Cancer Foundation) since 2021 and a member of the board of the Swiss Cancer League since 2017. At the same time, Solange Peters has always been politically involved in health issues and was a Lausanne city councillor for over 15 years.

With Solange Peters, a medical specialist from French-speaking Switzerland who knows the entire spectrum of healthcare, will be represented on the Board of Directors of the Galenica Group. Solange Peters has comprehensive experience and expertise with regard to collaboration between the various service providers: from the treatment of patients in hospitals, to further care by doctors and pharmacists, to home care services and interfaces with other service providers such as health insurers and the pharmaceutical industry.

Jörg Zulauf (1958) studied law at the University of Zurich (lic. jur.). He graduated with a degree in law from Zurich and an MBA from the University of California (UCLA), Los Angeles, USA. He began his professional career in the pharmaceutical industry, occupying senior positions at the pharmaceutical company Roche in Switzerland, Korea and Germany for 11 years, most recently as Head of the global Vitamin World Service department (Finance & IT).

In 2000, Jörg Zulauf joined Migros-Genossenschafts-Bund Zürich, where he headed the Finance Department as Vice Chairman of the Corporate Executive Committee until 2022 and was a member of the Retail, Finance and Audit committees. He was also a member of the Board of Directors and Vice Chairman of various Migros subsidiaries such as Globus, Hotelplan Holding AG, and Migros Bank AG. Jörg Zulauf also chaired the Foundation Board of the Migros Pension Fund for over 20 years. In addition to his wide-ranging knowledge and many years of experience as CFO, particularly in M&A, Jörg Zulauf brings a broad range of retail expertise to the Galenica Group. He has an excellent knowledge of the Swiss retail market, maintains an extensive network and is highly experienced in dealing with a wide range of stakeholders. His operational retail know-how and market knowledge will ideally complement the competencies of the Board of Directors. With the election of Markus R. Neuhaus as Chairman of the Board of Directors, the Board of Directors plans to appoint Jörg Zulauf as Chairman of the Audit & Risk Committee.

[Download photos](#)

Dates for the diary

7 March 2023: publication of the 2022 results for the Galenica Group
3 May 2023: Annual General Meeting of Galenica Ltd.
8 August 2023: publication of the half-year results for 2023

For further information, please contact:

Media Relations:

Christina Hertig, Head of Corporate Communications
Tel. +41 58 852 85 17
E-mail: media@galenica.com

Investor Relations:

Felix Burkhard, CFO
Tel. +41 58 852 85 31
E-mail: investors@galenica.com

Galenica is the leading fully integrated healthcare provider in Switzerland. With over 500 own, joint venture and independent partner pharmacies, Galenica operates the largest network of pharmacies in Switzerland. In addition, Galenica develops and offers well-known own consumer brands and products and exclusive brands and products from business partners, as well as offering a variety of on-site health services and tests for customers. Galenica is also the leading provider of both pre-wholesale and wholesale distribution services and database services in the Swiss healthcare market. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALE, security number 36,067,446). Additional information concerning Galenica can be found at www.galenica.com.